TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05142189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT116
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT116
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT116
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT116
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: intravenous infusion
Study: NCT05494762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-B167
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-B167
Description: Intravenous administration
Study: NCT05142189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTLA4 antibody
Description: intravenous infusion
Study: NCT06011577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT06420765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Solution or suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.
Study: NCT05993650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratuar Muscle Training Group
Description: Inspiratory muscle training will be done for 15 minutes/session, 2 times/day, or 30 minutes/day if tolerated, 5-7 days/week (one under supervision and others at home), for a total of 6 weeks. Applications made at home will be followed with a diary. Inspiratory muscle training will be performed using an inspiratory muscle training device (PowerBreathe®) working with the threshold loading principle.In the first week of the training, 30-50% of the maximal inspiratory pressure (MIP) measured in the initial evaluation of the individual will be adjusted according to the patient's tolerance, and inspiratory muscle training will be performed. Respiratory muscle strength measurement will be repeated every week in the individuals in the training group. 30-50% of the new MIP value obtained will be calculated and adjusted by calculating the new training workload for the application of inspiratory muscle training in the following weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thoracic Expansion Exercise Group
Description: Individuals in this group will be given thoracic expansion exercises and patient education. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of inhale a deep breathing + holding the deep breath for 3 seconds + slowly exhale all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks.
Study: NCT06445608

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Mechanical Circulatory Support
Description: Patients are randomized to receive one of two types of percutaneous mechanical circulatory support devices during a high-risk PCI procedure.
Study: NCT06007430

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule / Capsules per oral / once daily / 60 days duration
Study: NCT05494762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous administration
Study: NCT06203145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: A reduction in serum FLCs level of more than 80% by day 14 of BCD is defined BCD-AutoHSCT group; A reduction in serum FLCs level of less than 80% by day 14 of BCD is defined BCD-KPD-AutoHSCT group.
Study: NCT05595382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Appeal
Description: Participants will be presented with a short vignette about a child undergoing cancer treatment and needing a bone marrow transplant in order to survive cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rational Appeal
Description: Participants will be presented with data regarding the importance of considering race/ethnicity when looking for a bone marrow transplant donor and the likelihood of finding a match based on the patient's racial/ethnic background.
Study: NCT05882071

Intervention type: DRUG
Intervention: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
Description: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)

Intervention type: DRUG
Intervention: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
Description: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
Study: NCT06142747

Intervention type: DIAGNOSTIC_TEST
Intervention: Super-Resolution Ultrasound Imaging of Erythrocytes (SURE)
Description: Research ultrasound sequence for tracking erythrocytes and thereby generating a super-resolution image of the vasculature.

Intervention type: DIAGNOSTIC_TEST
Intervention: Super-Resolution Ultrasound Imaging of Erythrocytes (SURE)
Description: Research ultrasound sequence for tracking erythrocytes and thereby generating a super-resolution image of the vasculature.

Intervention type: DIAGNOSTIC_TEST
Intervention: Super-Resolution Ultrasound Imaging of Erythrocytes (SURE)
Description: Research ultrasound sequence for tracking erythrocytes and thereby generating a super-resolution image of the vasculature.
Study: NCT06274333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.5 mic/kg
Description: Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol 1mg/kg
Description: Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 10mg/kg
Description: Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 10mg/kg
Description: Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
Study: NCT06269666

Intervention type: DEVICE
Group type: OTHER
Intervention: P200TxE
Description: SLO and OCT imaging
Study: NCT04494711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Functional Literacy for Adults
Description: A 5 week physical literacy for program focused on virtual knowledge translation strategies to improve function and mobility for adults with multiple chronic conditions. This is a population -based approach to rehabilitation
Study: NCT04873856

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The four dimensions of MINDNUT are described below:~Nutritional plan: is conducted in collaboration with the participant based on nutritional registration and information about routines and habits to reach a daily protein target of 1.5 g/kg/day. The nutritional plan is adjusted at the regular contact, and nutritional supplementation will be handed out to the participant.~Friendly reminder/informal caregiver: is a friendly reminder that encourage the participant to follow the nutritional plan and to ask for support (a note to hang on the refrigerator). The informal caregiver is a person with close contact to the participant.~Regular contacts: The participant will be contacted on regular basis (with an interval of 7-14 days) via phone and besides nutritional plan, this conversation will be used to talk about well-being, compliance and potential side-effects.~Weight diary: participants is instructed in keeping a weight diary which include registration of a daily weight.
Study: NCT06448143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigotindisulfonate sodium 0.8% injection
Description: Experimental contrast dye for diagnostic procedures, commonly used as a visualization aid in pelvic and abdominal surgeries, as well as for evaluating ureteral patency.
Study: NCT06312670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386
Description: 600 mg orally administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg administered orally once daily, with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: LHRH agonist/antagonist or orchiectomy
Study: NCT06460051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary nerve block
Description: Ultrasound-guided, suprazygomatic approach, infrazygomatic window

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary nerve block
Description: Ultrasound-guided, suprazygomatic approach, infrazygomatic window
Study: NCT05157893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality based analgesic therapy
Description: The intervention is a single 15 min VR therapy. The VR therapy is consisted of VR device and software. The model of VR device used is Pico Neo 3 Pro. The software run on the VR device delivers two types of contents: 1) A 7min of computer-generated 360 video of underwater scene with therapeutic music to distract patients' attention on pain and make patients passively relax. 2) An 8min guided relaxation in which patients are transported to seaside with narrative to achieve image and breathing relaxation.
Study: NCT05106764

Intervention type: OTHER
Intervention: No intervention
Description: This is non-interventional study.
Study: NCT05977530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-rescue training
Description: children will receive training for self-rescue if they are alone in water
Study: NCT06109285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iROP DL
Description: First, to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by technicians in the neonatal intensive care unit (NICU) setting to detect more than mild ROP (MTMROP), defined as type 2 or worse from the Early Treatment for ROP study) compared to an image-based reference standard diagnosis (RSD).
Study: NCT05828719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Revascularization indication~1. Diameter stenosis \>90% by visual assessment~2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)~3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.~   * Left main artery~  * Proximal to mid left anterior descending artery~  * Proximal left circumflex artery in left dominant coronary arterial system~  * Proximal to distal right coronary artery in right dominant coronary arterial system
Study: NCT06381973

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ELTGOL_Physio
Description: The subject will be asked to slowly exhale with the glottis opened in the right lateral posture. The physiotherapist will accompany the subject by gently applying manual pressure on the chest wall and the abdomen during expiratory phases.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ELTGOL_Auto
Description: The subject will be asked to slowly exhale with the glottis opened in the right lateral posture. The physiotherapist will not intervene in this arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP
Description: The subject will be asked to exhale through a positive expiratory pressure (PEP) device (Threshold PEP) while being in the right lateral posture.
Study: NCT05037500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study: NCT06381973

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1L-Tidal-Breathing
Description: The subject will be asked to breath with a fixed tidal-breathing of 1 liter per breath (monitored via a spirometer) while being in the right lateral posture.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous Breathing
Description: The subject will be asked to breath spontaneously while being in the right lateral posture.
Study: NCT05037500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study: NCT05549882

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06444633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Sensitization + Household visit + Information + Free pre-emptive distribution of ORS+Zinc
Description: The intervention will involve the following: 1) The communities will be sensitized on the importance of ORS and Zinc use for the treatment of child diarrhea, by the Clinton Health Access Initiative (CHAI). 2) Campaigners recruited by CHAI will visit each household in their catchment area that contain at child under 5 years old. 3) During the distribution visits, the campaigners will train caregivers on the dangers of diarrhea and the importance of ORS and zinc use, among other things (including how to prepare, use, and store ORS/zinc, benefits of the treatments, recommended health behaviors such as seeking care, and encouraging basic handwashing and hygiene practices). The caregivers will also receive a flyer describing the same information in their local language, for future reference. 4) Campaigners will then distribute two ORS and zinc co-packs (each co-pack contains two sachets of ORS and 10 tablets of zinc) for free for each child under the age of five in the household.
Study: NCT06445608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Mechanical Circulatory Support
Description: Patients are randomized to receive one of two types of percutaneous mechanical circulatory support devices during a high-risk PCI procedure.
Study: NCT05836155

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention
Description: multispecies probiotic
Study: NCT05174689

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Exercise challenge in the cold chamber (ECC)
Description: Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Exercise challenge in the cold chamber (ECC)
Description: Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: mRNA profile
Description: Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: mRNA profile
Description: Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: mRNA profile
Description: Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.
Study: NCT05800002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Description: Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on intravascular ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on angiography.
Study: NCT04584320

Intervention type: OTHER
Intervention: Stool sample
Description: Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale

Intervention type: OTHER
Intervention: Stool sample
Description: Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
Study: NCT06182033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-mediated pivotal response training
Description: Teachers support children in the implementation of three strategies directed toward a target child identified as having language impairment and as isolated from the classroom social network.
Study: NCT05810311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roxadustat
Description: The group will receive Roxadustat (Evrenzo) three times weekly at an initial dose of 70mg (for body weight \<100.0 kg) or 100 mg (for body weight weight ≥100.0 kg). The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia.
Study: NCT06311227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05174689

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: standard diagnostic
Description: bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
Study: NCT05810311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoietin Alfa
Description: The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week. The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia.
Study: NCT06050512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells.
Study: NCT05174689

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: standard diagnostic
Description: bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: standard diagnostic
Description: bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
Study: NCT06343207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussive massage gun therapy
Description: Between pre and post-test, there was a one and half minute period during which each participant were in a prone position on a medical examination bed. The experimental PT groups received a 30-second triceps surae massage on each limb, while the control group maintained the same prone position without massage. The massage gun was set to 2100bpm and 1 bar of surface pressure was indicated by the device. The massage gun movement was performed according to the manufactu'er's instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussive massage gun therapy
Description: Between pre and post-test, there was a one and half minute period during which each participant were in a prone position on a medical examination bed. The experimental PT groups received a 30-second triceps surae massage on each limb, while the control group maintained the same prone position without massage. The massage gun was set to 2100bpm and 1 bar of surface pressure was indicated by the device. The massage gun movement was performed according to the manufactu'er's instructions.